IP Library › Granted Patent US 12,653,923
Granted Patent B2
US 12,653,923 · App. 17/791,249 · Granted Jun 16, 2026

Antimicrobial fibres

Inventors: Colin Raymond Bradford (Keighley, GB); Michael David Perkins (Macclesfield, GB); Benjamin Alexander Harrison (Sandbach, GB); Wayne Lee Bonnefin (Chester, GB); Ander Bugedo Albizuri (Chester, GB)
Assignee: Advanced Medical Solutions Limited
A61L15/28A61L15/44A61L2300/206A61L2300/404
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,653,923
App. No.
17/791,249
Granted
Jun 16, 2026
Kind
B2
Abstract

Described is a method of manufacturing carboxymethyl cellulose (CMC) fibres containing an antimicrobial, the fibres being suitable for use in the preparation of wound dressings, wherein the antimicrobial is selected from the group consisting of a biguanide, a biguanide derivative, octenidine, taurolidine, and a combination of two or more thereof, the method comprising, submerging CMC fibres comprising at least 95 wt % carboxymethylcellulose on a dry weight basis in a treatment solution for a duration adequate to provide the CMC fibres containing an antimicrobial, the treatment solution comprising the antimicrobial and at least 70 wt % of a water-miscible organic solvent selected from C 1 -C 4 alkanols, C 3 -C 5 ketones, and a combination of two or more thereof. Anti-microbial CMC fibres obtained by the methods and wound dressings containing such fibres are also described.

Claims (27)

1 . A method of manufacturing carboxymethylcellulose (CMC) fibres containing an antimicrobial, the fibres being suitable for use in the preparation of wound dressings, wherein the antimicrobial is selected from the group consisting of a biguanide, a biguanide derivative, octenidine, taurolidine, and a combination of two or more thereof, the method comprising:

submerging CMC fibres comprising at least 95 wt % carboxymethylcellulose on a dry weight basis in a treatment solution, the treatment solution comprising:

a) the antimicrobial; and

b) at least 70 wt % of a water-miscible organic solvent selected from C 1 -C 4 alkanols, C 3 -C 5 ketones, and a combination of two or more thereof;

for a duration adequate to provide the CMC fibres containing an antimicrobial.

2 . The method according to claim 1 , wherein the CMC fibres submerged in the treatment solution are continuous filament fibres.

3 . The method according to claim 1 wherein the antimicrobial is polyhexamethylene biguanide (PHMB).

4 . The method according to claim 1 , wherein the treatment solution comprises from 1-10 wt % of the antimicrobial agent relative to the total weight of the solution.

5 . The method according to claim 1 , wherein the treatment solution comprises water in an amount of from 5-25 wt % relative to the weight of the solution.

6 . The method according to claim 1 , wherein the treatment solution comprises the water-miscible organic solvent in an amount of from 70-85 wt % relative to the total weight of the solution.

7 . The method according to claim 1 , wherein the water-miscible organic solvent is selected from one or more of methanol, ethanol, propanol, isopropanol, and acetone.

8 . The method according to claim 7 , wherein the water-miscible organic solvent comprises at least 90 wt % ethanol relative to the total weight of the water-miscible organic solvent, optionally at least 95 wt % ethanol.

9 . The method according to claim 1 , wherein the step of submerging in CMC fibres in the treatment solution is preceded by a process of forming the CMC fibres, the process of forming the CMC fibres comprising:

reacting cellulose fibres with a carboxymethylating agent to provide carboxymethylcellulose (CMC) fibres.

10 . The method according to claim 1 , wherein the step of submerging the CMC fibres in the treatment solution is preceded by a step of washing the CMC fibres with a pre-treatment wash solution.

11 . The method according to claim 1 , wherein the treatment solution is maintained at a temperature within the range of from 20° C. to 50° C. during the submerging step.

12 . The method according to claim 1 , wherein the CMC fibres are submerged in the treatment solution for a duration of from 15 to 35 minutes.

13 . The method according to claim 1 , wherein the step of submerging the CMC fibres is followed by washing the CMC fibres containing antimicrobial with a post-treatment wash solution, the post-treatment wash solution comprising:

(i) at least 98 wt % of a water-miscible organic solvent selected from C 1 -C 4 alkanols, C 3 -C 5 ketones, and a combination of two or more thereof; and optionally

(ii) a spin finish agent, optionally from 0.1-2.0 wt % spin finish agent.

14 . The method according to claim 1 , wherein the CMC fibres comprise from 0.05 to 0.8 carboxymethyl groups per glucose unit as determined by potentiometric titration.

15 . A carboxymethylcellulose (CMC) fibre containing an antimicrobial within the polymer matrix of the carboxymethylcellulose fibre, wherein the antimicrobial is selected from a biguanide, a biguanide derivative, octenidine, taurolidine, and a combination of two or more thereof, for use in the preparation of wound dressings, wherein the antimicrobial is dispersed throughout the polymer matrix of the CMC fibre.

16 . The CMC fibre containing an antimicrobial according to claim 15 , wherein the antimicrobial is present in the fibre in an amount of from 0.3 to 1.1 wt %, relative to the total weight of the fibre.

17 . The CMC fibre containing an antimicrobial according to claim 15 , wherein the antimicrobial is polyhexamethylene biguanide (PHMB).

18 . A woven, non-woven or knitted material comprising CMC fibres according to claim 15 .

19 . A non-woven material comprising entangled CMC fibres according to claim 15 , wherein the non-woven material exhibits a conformability characterised by an overhang length of up to 6.5 cm in the long dimension, as determined by the Cantilever method described in ASTM D1388-08.

20 . A wound dressing comprising CMC fibres according to claim 15 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2022
From: BRADFORD, COLIN RAYMOND; PERKINS, MICHAEL DAVID; HARRISON, BENJAMIN ALEXANDER; BONNEFIN, WAYNE LEE; BUGEDO ALBIZURI, ANDER
To: ADVANCED MEDICAL SOLUTIONS LIMITED
Reel/Frame 060428/0188 →
Priority Claims (1)
GB 2000250 · Jan 8, 2020 · national
Continuity (1)
Related Publication 20230050073A1 · Feb 16, 2023
References Cited (214)
US 5856248A · Weinberg · 1999 [cited by applicant]
US 6080420A · Qin et al. · 2000 [cited by applicant]
US 6369289B1 · Orr, III · 2002 [cited by applicant]
US 6706279B1 · Hazzi · 2004 [cited by applicant]
US 7704523B2 · Serafica et al. · 2010 [cited by applicant]
US 9402770B2 · Moghe et al. · 2016 [cited by applicant]
US 9869037B2 · Agboh · 2018 [cited by applicant]
US 9907702B2 · Kipke et al. · 2018 [cited by applicant]
US 10342707B2 · Wang et al. · 2019 [cited by applicant]
US 20020012693A1 · Cohen et al. · 2002 [cited by applicant]
US 20020064551A1 · Edwards et al. · 2002 [cited by applicant]
US 20020177828A1 · Batich et al. · 2002 [cited by applicant]
US 20030049300A1 · Terry · 2003 [cited by applicant]
US 20030149406A1 · Martineau et al. · 2003 [cited by applicant]
US 20030203012A1 · Serafica et al. · 2003 [cited by applicant]
US 20030203991A1 · Schottman et al. · 2003 [cited by applicant]
US 20040116014A1 · Soerens et al. · 2004 [cited by applicant]
US 20040116551A1 · Terry · 2004 [cited by applicant]
US 20040116885A1 · Soerens et al. · 2004 [cited by applicant]
US 20040142019A1 · Serafica et al. · 2004 [cited by applicant]
US 20040153040A1 · Martineau et al. · 2004 [cited by applicant]
US 20040161453A1 · Serafica et al. · 2004 [cited by applicant]
US 20050214541A1 · Berrada et al. · 2005 [cited by applicant]
US 20060211972A1 · Nielsen et al. · 2006 [cited by applicant]
US 20070026056A1 · Rolf · 2007 [cited by applicant]
US 20070179291A1 · Thibodeau et al. · 2007 [cited by applicant]
US 20070237812A1 · Patel et al. · 2007 [cited by applicant]
US 20080206293A1 · Toreki et al. · 2008 [cited by applicant]
US 20080249206A1 · Flohr et al. · 2008 [cited by applicant]
US 20080262455A1 · Soerens et al. · 2008 [cited by applicant]
US 20080312572A1 · Riesinger et al. · 2008 [cited by applicant]
US 20090022780A1 · Scherer et al. · 2009 [cited by applicant]
US 20090022801A1 · Vachon · 2009 [cited by applicant]
US 20090148395A1 · Fugmann et al. · 2009 [cited by applicant]
US 20090186332A1 · Manders et al. · 2009 [cited by applicant]
US 20090263469A1 · Rohrer et al. · 2009 [cited by applicant]
US 20090306157A1 · Rohrer et al. · 2009 [cited by applicant]
US 20100036334A1 · Heagle et al. · 2010 [cited by applicant]
US 20100055142A1 · Heagle et al. · 2010 [cited by applicant]
US 20100055158A1 · Vitaris et al. · 2010 [cited by applicant]
US 20100055437A1 · Fink et al. · 2010 [cited by applicant]
US 20100129633A1 · Law · 2010 [cited by applicant]
US 20100215723A1 · Yao · 2010 [cited by applicant]
US 20100247544A1 · Vachon · 2010 [cited by applicant]
US 20100260809A1 · Valentova et al. · 2010 [cited by applicant]
US 20100262090A1 · Riesinger · 2010 [cited by applicant]
US 20110104227A1 · Andjelic et al. · 2011 [cited by applicant]
US 20110171283A1 · Riesinger · 2011 [cited by applicant]
US 20110213286A1 · Riesinger · 2011 [cited by applicant]
US 20110238025A1 · Law · 2011 [cited by applicant]
US 20110256185A1 · Yang et al. · 2011 [cited by applicant]
US 20120215193A1 · Siniaguine et al. · 2012 [cited by applicant]
US 20120232502A1 · Lowing · 2012 [cited by applicant]
US 20120276183A1 · Bradford · 2012 [cited by applicant]
US 20120310186A1 · Moghe et al. · 2012 [cited by applicant]
US 20130150764A1 · Patel et al. · 2013 [cited by applicant]
US 20130171224A1 · Percival et al. · 2013 [cited by applicant]
US 20130231394A1 · Arndt et al. · 2013 [cited by applicant]
US 20140044758A1 · Wang et al. · 2014 [cited by applicant]
US 20140163485A1 · Knill et al. · 2014 [cited by applicant]
US 20140220842A1 · Koltzenburg et al. · 2014 [cited by applicant]
US 20140256925A1 · Catchmark et al. · 2014 [cited by applicant]
US 20140309574A1 · Cotton · 2014 [cited by applicant]
US 20150010612A1 · Vogt et al. · 2015 [cited by applicant]
US 20150094672A1 · Blucher et al. · 2015 [cited by applicant]
US 20150118283A1 · Von Blucher et al. · 2015 [cited by applicant]
US 20150135644A1 · Mo et al. · 2015 [cited by applicant]
US 20150157758A1 · Blucher et al. · 2015 [cited by applicant]
US 20150209187A1 · Gutierrez et al. · 2015 [cited by applicant]
US 20150283287A1 · Agarwal et al. · 2015 [cited by applicant]
US 20150335492A1 · Tao et al. · 2015 [cited by applicant]
US 20150367021A1 · Wibaux · 2015 [cited by applicant]
US 20160030254A1 · Maharaj et al. · 2016 [cited by applicant]
US 20160095754A1 · Andrews et al. · 2016 [cited by applicant]
US 20160095951A1 · Locke et al. · 2016 [cited by applicant]
US 20160101165A1 · Salamone et al. · 2016 [cited by applicant]
US 20160101207A1 · Parsons et al. · 2016 [cited by applicant]
US 20160158403A1 · Watson · 2016 [cited by applicant]
US 20160270962A1 · Wang et al. · 2016 [cited by applicant]
US 20160317625A1 · Dicosmo · 2016 [cited by applicant]
US 20170021050A1 · Carlsson et al. · 2017 [cited by applicant]
US 20170151314A1 · Salamone et al. · 2017 [cited by applicant]
US 20170216478A1 · Lorenzoni · 2017 [cited by applicant]
US 20170231822A1 · Hoggarth et al. · 2017 [cited by applicant]
US 20170239095A1 · Hoggarth et al. · 2017 [cited by applicant]
US 20170258956A1 · Flach et al. · 2017 [cited by applicant]
US 20170258957A1 · Flach et al. · 2017 [cited by applicant]
US 20170367895A1 · Holm et al. · 2017 [cited by applicant]
US 20170367896A1 · Holm et al. · 2017 [cited by applicant]
US 20180008742A1 · Hoggarth et al. · 2018 [cited by applicant]
US 20180014974A1 · Hoggarth et al. · 2018 [cited by applicant]
US 20180014975A1 · Hoggarth et al. · 2018 [cited by applicant]
US 20180028713A1 · Agarwal et al. · 2018 [cited by applicant]
US 20180042980A1 · Datt et al. · 2018 [cited by applicant]
US 20180044847A1 · Swamy et al. · 2018 [cited by applicant]
US 20180071147A1 · Marz et al. · 2018 [cited by applicant]
US 20180094369A1 · Koltzenburg et al. · 2018 [cited by applicant]
US 20180207323A1 · Chen et al. · 2018 [cited by applicant]
US 20180214596A1 · Gupta et al. · 2018 [cited by applicant]
US 20180303674A1 · Barrows et al. · 2018 [cited by applicant]
US 20180353637A1 · Ko · 2018 [cited by applicant]
US 20180368401A1 · Swamy et al. · 2018 [cited by applicant]
US 20190046488A1 · Rosenblatt et al. · 2019 [cited by applicant]
US 20190117464A1 · Seo et al. · 2019 [cited by applicant]
US 20190133131A1 · Percival et al. · 2019 [cited by applicant]
US 20190160197A1 · Gardiner · 2019 [cited by examiner]
US 20190282453A1 · Hoffmann et al. · 2019 [cited by applicant]
US 20190290676A1 · Zhang et al. · 2019 [cited by applicant]
US 20190307904A1 · Ballamy · 2019 [cited by applicant]
US 20190351092A1 · Silver et al. · 2019 [cited by applicant]
US 20190380880A1 · Carlsson · 2019 [cited by applicant]
US 20200016291A1 · Wibaux · 2020 [cited by applicant]
US 20200114040A1 · Waite et al. · 2020 [cited by applicant]
US 20200129339A1 · Drury et al. · 2020 [cited by applicant]
US 20200129648A1 · Drury et al. · 2020 [cited by applicant]
US 20200139002A1 · Dudnyk et al. · 2020 [cited by applicant]
US 20200179445A1 · Buffa et al. · 2020 [cited by applicant]
US 20200188183A1 · Hamerslagh et al. · 2020 [cited by applicant]
US 20200188550A1 · Dagger et al. · 2020 [cited by applicant]
US 20200197559A1 · Bourdillon et al. · 2020 [cited by applicant]
US 20200289701A1 · Hall et al. · 2020 [cited by applicant]
US 20200297892A1 · Silcock · 2020 [cited by applicant]
US 20200345557A1 · Waite et al. · 2020 [cited by applicant]
US 20200345888A1 · O'gara et al. · 2020 [cited by applicant]
US 20200375802A1 · Metcalf et al. · 2020 [cited by applicant]
US 20210085819A1 · Brewster et al. · 2021 [cited by applicant]
US 20210113733A1 · Nielsen et al. · 2021 [cited by applicant]
US 20210146000A1 · Dagger et al. · 2021 [cited by applicant]
US 20210146002A1 · Kharkar et al. · 2021 [cited by applicant]
US 20210169926A1 · Abbott et al. · 2021 [cited by applicant]
US 20210170041A1 · Luukko et al. · 2021 [cited by applicant]
US 20210244431A1 · Hentrich et al. · 2021 [cited by applicant]
US 20210259890A1 · Carty et al. · 2021 [cited by applicant]
US 20210290815A1 · Parsons et al. · 2021 [cited by applicant]
US 20210346312A1 · Hengsberger et al. · 2021 [cited by applicant]
US 20210361820A1 · Bourdillon et al. · 2021 [cited by applicant]
US 20220023490A1 · Locke et al. · 2022 [cited by applicant]
US 20220118035A1 · Buzzi · 2022 [cited by applicant]
US 20220193300A1 · Eliyahu-Gross et al. · 2022 [cited by applicant]
US 20220280682A1 · Bodkhe et al. · 2022 [cited by applicant]
US 20220347339A1 · Derrick et al. · 2022 [cited by applicant]
US 20240050281A1 · Leeb et al. · 2024 [cited by applicant]
CN 102462860A · 2012 [cited by applicant]
CN 102580136A · 2012 [cited by applicant]
CN 107137749A · 2017 [cited by applicant]
DE 102006001954 · 2007 [cited by examiner]
DE 102006001954A1 · 2007 [cited by applicant]
EP 1057481A1 · 2000 [cited by applicant]
EP 1438975A1 · 2004 [cited by applicant]
EP 3061864A1 · 2016 [cited by applicant]
EP 3078360A1 · 2016 [cited by applicant]
EP 3281614A1 · 2018 [cited by applicant]
EP 3434237A1 · 2019 [cited by applicant]
FR 2972355A3 · 2012 [cited by applicant]
GB 821113A · 1959 [cited by applicant]
GB 2401879A · 2004 [cited by applicant]
GB 2489541A · 2012 [cited by applicant]
GB 2531344A · 2016 [cited by applicant]
GB 2531345A · 2016 [cited by applicant]
GB 2537008A · 2016 [cited by applicant]
GB 2537009A · 2016 [cited by applicant]
GB 2537010A · 2016 [cited by applicant]
GB 2554651A · 2018 [cited by applicant]
GB 2489947B · 2018 [cited by applicant]
GB 2579800A · 2020 [cited by applicant]
JP 63021979A · 1988 [cited by examiner]
JP S6321979A · 1988 [cited by applicant]
WO 0028978A1 · 2000 [cited by applicant]
WO 03061538A1 · 2003 [cited by applicant]
WO 0247737A1 · 2003 [cited by applicant]
WO 03092756A1 · 2003 [cited by applicant]
WO 2003093357A1 · 2003 [cited by applicant]
WO 2004062600A2 · 2004 [cited by applicant]
WO 2005030279A1 · 2005 [cited by applicant]
WO 2007120616A2 · 2007 [cited by applicant]
WO 2008122929A1 · 2008 [cited by applicant]
WO 2009043839A1 · 2009 [cited by applicant]
WO 2009080218A2 · 2009 [cited by applicant]
WO 2012062139A1 · 2012 [cited by applicant]
WO 2012092813A1 · 2012 [cited by applicant]
WO 2012122956A1 · 2012 [cited by applicant]
WO 2012160217A1 · 2012 [cited by applicant]
WO 2012171916A1 · 2012 [cited by applicant]
WO 2012171920A1 · 2012 [cited by applicant]
WO 2013113906A1 · 2013 [cited by applicant]
WO 2013164016A1 · 2013 [cited by applicant]
WO 2014020133A2 · 2014 [cited by applicant]
WO 2015173547A1 · 2015 [cited by applicant]
WO 2016057788A1 · 2016 [cited by applicant]
WO 2016107856A1 · 2016 [cited by applicant]
WO 2016108041A1 · 2016 [cited by applicant]
WO 2016115637A1 · 2016 [cited by applicant]
WO 2016135038A1 · 2016 [cited by applicant]
WO 2016206638A1 · 2016 [cited by applicant]
WO 2017085436A1 · 2017 [cited by applicant]
WO WO2017085436 · 2017 [cited by examiner]
WO 2017108770A1 · 2017 [cited by applicant]
WO 2018023021A1 · 2018 [cited by applicant]
WO 2018078084A1 · 2018 [cited by applicant]
WO 2018125993A1 · 2018 [cited by applicant]
WO 2019011000A1 · 2019 [cited by applicant]
WO 2020261187A1 · 2020 [cited by applicant]
WO 2021009713A1 · 2021 [cited by applicant]
WO 2021015631A1 · 2021 [cited by applicant]
WO 2021240271A1 · 2021 [cited by applicant]
JP63021979A abstract translation (Year: 1988). [cited by examiner]
Halib et al., “Potential Applications of Nanocellulose-Containing Materials in the Biomedical Field”, Materials, 2017, 31 pages. [cited by applicant]
U.S. Appl. No. 62/098,058, filed Dec. 30, 2014 in the name of 3M Innovative Properties Company. [cited by applicant]
U.S. Appl. No. 62/112,74, filed Feb. 6, 2015 in the name of 3M Innovative Properties Company. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/GB2021/050037 dated Jul. 12, 2022 (6 pages). [cited by applicant]
United Kingdom Patent Office Search report for Application No. GB2000250.7 dated Jul. 24, 2020 (5 pages). [cited by applicant]
PRC National Intellectual Property Administration Supplementary Novelty Search Report for Application No. GC2021-41250 dated Apr. 7, 2022 (4 pages). [cited by applicant]
United Kingdom Patent Office Further Search Report for Application No. GB2000250.7 dated Jan. 28, 2021, Claims Searched:28 and 29 in full and 30-33 and 35-38 in part (2 pages). [cited by applicant]
United Kingdom Patent Office Further Search Report for Application No. GB2000250.7 dated Jan. 28, 2021, Claims Searched: 34 in full and 35 in part (2 pages). [cited by applicant]